506067102 05/19/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6113817

SUBMISSION TYPE:	CORRECTIVE ASSIGNMENT
NATURE OF CONVEYANCE:	Corrective Assignment to correct the THE SPELLING OF ASSIGNEE EVOTEK (UK) LTD TO EVOTEC (UK) LTD previously recorded on Reel 052678 Frame 0467. Assignor(s) hereby confirms the SPELLING OF THE ASSIGNEE IS EVOTEC (UK) LTD.

CONVEYING PARTY DATA

Name	Execution Date
GARETH NEIL BRACE	06/12/2018
ROSE ELIZABETH CHAPPELL	06/12/2018
HERVE JEAN CLAUDE DEBOVES	06/12/2018
GREGORY FOULKES	06/12/2018
ROBERT JAMES TOWNSEND	06/12/2018

RECEIVING PARTY DATA

Name:	EVOTEC (UK) LTD
Street Address:	114 INNOVATION DRIVE
Internal Address:	MILTON PARK
City:	ABINGDON, OXFORDSHIRE
State/Country:	UNITED KINGDOM
Postal Code:	OX14 4RZ

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16619573

CORRESPONDENCE DATA

Fax Number: (312)913-0002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3129130001

Email: neth@mbhb.com, docketing@mbhb.com

Correspondent Name: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP

Address Line 1:300 SOUTH WACKER DRIVEAddress Line 4:CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER:	19-2221-WO-US
NAME OF SUBMITTER:	STEVEN J. SARUSSI
SIGNATURE:	/Steven J. Sarussi/

PATENT 506067102 REEL: 052706 FRAME: 0397

DATE SIGNED: 05/19/2020 **Total Attachments: 35** source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page1.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page2.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page3.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page4.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page5.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page6.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page7.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page8.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page9.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page10.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page11.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page12.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page13.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page14.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page15.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page16.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page17.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page18.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page19.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page20.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page21.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page22.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page23.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page24.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page25.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page26.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page27.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page28.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page29.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page30.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page31.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page32.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page33.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page34.tif source=PF0110-US-PCT - Inventors to Evotec Cover Sheet with assignment#page36.tif

506062495 05/15/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6109209

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
GARETH NEIL BRACE	06/12/2018
ROSE ELIZABETH CHAPPELL	06/12/2018
HERVE JEAN CLAUDE DEBOVES	06/12/2018
GREGORY FOULKES	06/12/2018
ROBERT JAMES TOWNSEND	06/12/2018

RECEIVING PARTY DATA

Name:	EVOTEK (UK) LTD
Street Address:	114 INNOVATION DRIVE
Internal Address:	MILTON PARK
City:	ABINGDON, OXFORDSHIRE
State/Country:	UNITED KINGDOM
Postal Code:	OX14 4RZ

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16619573

CORRESPONDENCE DATA

Fax Number: (312)913-0002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3129130001

neth@mbhb.com, docketing@mbhb.com Email:

MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP **Correspondent Name:**

Address Line 1: 300 SOUTH WACKER DRIVE Address Line 4: CHICAGO, ILLINOIS 60606

ATTORNEY DOCKET NUMBER: 19-2221-WO-US NAME OF SUBMITTER: STEVEN J. SARUSSI SIGNATURE: /Steven J. Sarussi/ **DATE SIGNED:** 05/15/2020

Total Attachments: 35

CONFIRMATORY ACKNOWLEDGEMENT, ASSIGNMENT AND UNDERTAKING AGREEMENT

THIS AGREEMENT is made the (day of SUNL 2018 between

(1) Gareth Neil Brace

("THE INVENTOR");

o/o Evotec (UK) Ltd 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UNITED KINGDOM

(2) Evotec (UK) Ltd

("EVOTEC")

114 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RZ

(3) UCB BIOPHARMA SPRL

("UCB BIOPHARMA")

Allée de la Recherche, 60 B-1070 Brussels BELGIUM

WHEREAS

- (A) The Inventor has been determined as being the sole inventor or one of the joint inventors of the invention or inventions entitled SPIROCYCLIC INDOLINES AS IL-17 MODULATORS and identified by the patent family reference PF0110 ("the Invention");
- (B) The Invention is described in a patent application ("the Application"), identified by the following short particulars, which patent application has with the consent of all the parties hereto been filed in the name of **UCB BIOPHARMA** with the patent office shown:

Patent Office	Filing Date	Application Number
LIK Patent Office	14 June 2017	1709456 6

- (C) It is the wish and intention of all the parties hereto that:
 - (i) the Application shall continue in the name of **UCB BIOPHARMA**;
 - (ii) any patent application or like application filed in any country or territory and being directed to the Invention (whether or not claiming priority under the Paris Convention or like arrangement from the Application and including all divisional applications, applications for patents of addition, continuation applications,

continuation-in-part applications, applications for re-issue national applications, patent term extensions, supplementary protection certificates, regional applications and international applications and like corresponding applications) ("Corresponding Application(s)") shall be in the name of and shall vest in UCB BIOPHARMA; and

(iii) any patent granted on the Application or on any Corresponding Application(s) shall be in the name of and shall vest in UCB BIOPHARMA.

NOW THIS AGREEMENT WITNESSETH:

- 1. THE INVENTOR ACKNOWLEDGES that:
 - a) he or she made the Invention as part of his or her normal employment duties and the circumstances were such that an invention might reasonably have been expected to result from the carrying out of his or her duties; and
 - b) all his or her right, title, and interest in the invention have transferred to **EVOTEC** by virtue of applicable Law.
- 2. All right, title and interest in the Invention have transferred from EVOTEC to UCB BIOPHARMA by virtue of an agreement dated 4 March 2014 and amendments thereof.

EVOTEC hereby agrees that **UCB BIOPHARMA** has and shall have the exclusive rights to the Invention and all patent applications and resulting patents pertaining to the Invention, as well as the exclusive right to apply for patents, or any other such protection of intellectual property rights for the Invention, including for the avoidance of doubt the Application and the Corresponding Application(s).

- 3. **EVOTEC** and **THE INVENTOR** ACKNOWLEDGE that all right, title and interest in the Invention thereof are vested in **UCB BIOPHARMA** and that **UCB BIOPHARMA** has the exclusive rights to:
 - (i) the Invention;
 - the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto UCB BIOPHARMA absolutely.

- 4. Insofar as the rights in the Invention and the Application are still vested in THE INVENTOR and/or EVOTEC and in consideration of One Dollar (\$1.00) and other good and valuable consideration in hand paid, the receipt and sufficiency whereof are hereby acknowledged, THE INVENTOR and/or EVOTEC HEREBY ASSIGNS to UCB BIOPHARMA:
 - (i) the Invention;
 - (ii) the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) the right to recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto **UCB BIOPHARMA** absolutely.

- 5. **UCB BIOPHARMA** HEREBY ACCEPTS all that is transferred to it under this Agreement.
- 6. EACH OF THE INVENTOR AND EVOTEC HEREBY UNDERTAKES to do or have done as and when required by UCB BIOPHARMA, or its nominee as UCB BIOPHARMA shall direct, and at the expense of UCB BIOPHARMA, any and all acts and things including the execution of documents necessary or expedient for perfecting the assignments contained herein and/or for giving effect to the wishes and intentions of the parties hereto.
- 7. EACH OF THE INVENTOR AND EVOTEC HEREBY AUTHORISES UCB BIOPHARMA or its nominee and the agents of any of them as UCB BIOPHARMA shall direct to insert here below at (*) the relevant application number and/or any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent Office for recordation of this document:

(*)	US Serial No :	
()	03 Senai No.	
and/or	PCT Application No:	
	Filing Date :	

- 8. IN THE EVENT THAT ANY OF THE TERMS OF THIS AGREEMENT is held to be invalid, the remainder of the terms shall continue in full force and effect.
- 9. THIS AGREEMENT SHALL BE CONSTRUED in all respects in accordance with law governing Prior Agreement.

IN WITNESS whereof the parties have caused this agreement to be duly executed on the day and year first above written.

This page remains without signatures on purpose – all signatures are executed on follow-up pages (5-7).

Gareth Neil Brace	
Signature: Place:	<u>Lid</u> Euke UK
Witness signature:	Gue 2 SIANUARIO TRANI
Address:	114. INNOVATION DRIVE, MILTON PARK, ARINGBON, OX14 4RZ
Place:	DOTEC OK
Witness signature:	22 Nea - 1
Name:	RICHARD JOHN MEARS
Address:	114 Innovation Drive, Millon Feche, Abingdon, OXI4 422
Place:	Evolute UK

Signed by THE INVENTOR

KAMEAN GASHIK

Signed for and on behalf of Evotec (UK) Ltd

Ву:

Address:

Place:

Name: KATHRYN WICKES

Signature: CUULLQ)

Signature: ABINGDON, UK

Witness signature: ACNOY CHOUS Name:

ACRONY CHOUS NEW

Witness signature: ARINGDON, UK

Illy INNOVATION DRIVE

ABING BON, UK

Signed for and or	behalf of UCB BIOPHARMA SPRL	
By: Name: St	phane DROUIN :	
Title: Vi	ce President, Head Group Intellectual Property	
Signature:		
Oiginature.		
Place:	y sloven vic	
	ΔΛ I	
Witness signature	E Delug Rys .	
Name:	SARAGI FRUMPHROVS	
Address:	<u>c10208 Ball Road</u>	
Place:	SLOWER UM	
Witness signature	: UARAGAROS	
Name:	KATE SOLBESC	
Address:	cho 200 Billi Read	
Place:	SLOURY, YK	

CONFIRMATORY ACKNOWLEDGEMENT, ASSIGNMENT AND UNDERTAKING AGREEMENT

THIS AGREEMENT is made the Lay of July 2018 between

(1) Rose Elizabeth CHAPPELL

("THE INVENTOR"):

c/o Evotec (UK) Ltd 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UNITED KINGDOM

(2) Evotec (UK) Ltd

("EVOTEC")

114 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RZ United Kingdom

(4) UCB BIOPHARMA SPRL

("UCB BIOPHARMA")

Allée de la Recherche, 60 B-1070 Brussels BELGIUM

WHEREAS

- (A) The Inventor has been determined as being the sole inventor or one of the joint inventors of the invention or inventions entitled **SPIROCYCLIC INDOLINES AS IL-17 MODULATORS** and identified by the patent family reference PF0110 ("the Invention");
- (B) The Invention is described in a patent application ("the Application"), identified by the following short particulars, which patent application has with the consent of all the parties hereto been filed in the name of **UCB BIOPHARMA** with the patent office shown:

Pate	nt Office	Filing Date	Application Number
UK F	Patent Office	14 June 2017	1709456.6

- (C) It is the wish and intention of all the parties hereto that:
 - (i) the Application shall continue in the name of **UCB BIOPHARMA**:
 - (ii) any patent application or like application filed in any country or territory and being directed to the Invention (whether or not claiming priority under the Paris Convention or like arrangement from the Application and including all divisional

applications, applications for patents of addition, continuation applications, continuation-in-part applications, applications for re-issue national applications, patent term extensions, supplementary protection certificates, regional applications and international applications and like corresponding applications) ("Corresponding Application(s)") shall be in the name of and shall vest in **UCB BIOPHARMA**; and

(iii) any patent granted on the Application or on any Corresponding Application(s) shall be in the name of and shall vest in **UCB BIOPHARMA**.

NOW THIS AGREEMENT WITNESSETH:

- 1. **THE INVENTOR** ACKNOWLEDGES that:
 - a) he or she made the Invention as part of his or her normal employment duties and the circumstances were such that an invention might reasonably have been expected to result from the carrying out of his or her duties; and
 - b) all his or her right, title, and interest in the invention have transferred to **EVOTEC** by virtue of applicable Law.
- 2. All right, title and interest in the Invention have transferred from **EVOTEC** to **UCB BIOPHARMA** by virtue of an agreement dated 1 May 2015 including amendments thereof.

EVOTEC hereby agrees that **UCB BIOPHARMA** has and shall have the exclusive rights to the Invention and all patent applications and resulting patents pertaining to the Invention, as well as the exclusive right to apply for patents, or any other such protection of intellectual property rights for the Invention, including for the avoidance of doubt the Application and the Corresponding Application(s).

- 3. **EVOTEC** and **THE INVENTOR** ACKNOWLEDGE that all right, title and interest in the Invention thereof are vested in **UCB BIOPHARMA** and that **UCB BIOPHARMA** has the exclusive rights to:
 - (i) the Invention;
 - (ii) the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto **UCB BIOPHARMA** absolutely.

- Insofar as the rights in the Invention and the Application are still vested in THE INVENTOR and/or EVOTEC and in consideration of One Dollar (\$1.00) and other good and valuable consideration in hand paid, the receipt and sufficiency whereof are hereby acknowledged, THE INVENTOR and/or EVOTEC HEREBY ASSIGNS to UCB BIOPHARMA:
 - (i) the Invention;
 - (ii) the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) the right to recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto UCB BIOPHARMA absolutely.

- 5. **UCB BIOPHARMA** HEREBY ACCEPTS all that is transferred to it under this Agreement.
- 6. EACH OF THE INVENTOR AND EVOTEC HEREBY UNDERTAKES to do or have done as and when required by UCB BIOPHARMA, or its nominee as UCB BIOPHARMA shall direct, and at the expense of UCB BIOPHARMA, any and all acts and things including the execution of documents necessary or expedient for perfecting the assignments contained herein and/or for giving effect to the wishes and intentions of the parties hereto.
- 7. EACH OF THE INVENTOR AND EVOTEC HEREBY AUTHORISES UCB BIOPHARMA or its nominee and the agents of any of them as UCB BIOPHARMA shall direct to insert here below at (*) the relevant application number and/or any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent Office for recordation of this document:

and/or P	US Serial No :	
FI	iling Date :	

- 8. IN THE EVENT THAT ANY OF THE TERMS OF THIS AGREEMENT is held to be invalid, the remainder of the terms shall continue in full force and effect.
- 9. THIS AGREEMENT SHALL BE CONSTRUED in all respects in accordance with law governing Prior Agreement.

IN WITNESS whereof the parties have caused this agreement to be duly executed on the day and year first above written.

This page remains without signatures on purpose – all signatures are executed on follow-up pages (5-7).

Signed by THE INVENTOR

Rose Elizabeth CHAPPELL

Signature:	16 Amgalla
Place:	SLÓUGH JUIC
Witness signature:	LASalflee_
Name:	<u>KATE SESCREGE</u>
Address:	c/0208 Bath Road
Place:	SLOVEY UK
Witness signature:	Shupryo
Name:	SWEAY HUMAKES
Address:	clo 208 Bath Read
Place:	SLOUGH, UK

Signed for and on behalf of Evotec (UK) Ltd KARLAN BASHIR KATHRYN WILKES Name: By: VP HUMAN RESOURCES Title: FINANCE DIRECTOR (OK) RUULKA Signature: Alincoon, UK ARINGDON, UK Place: Witness signature: HIM AND A Name: 114 Innsvation Drive Address: Abradon UK Place: Witness signature: Name: LONDVATION DRIVE , MILTON PARK Address:

ABING DON, UK

Place:

olgned	for and	on benaii	ບເບເລ	DIUPHAKI	na spre
Ву:	Name:	Stéphane	DROUI	N:	

Title: Vice President, Head Group Intellectual Property

Signature:

Place:

SLOUGH, UK

Witness signature:

Name:

SMAH HUMPMKYS

Address:

10208 Bath Road

Place:

SLOUGH, UK

Witness signature:

Name:

KATE SEDGEER

Address:

clo208 Bath Road

Place:

SLOWET, MIC

CONFIRMATORY ACKNOWLEDGEMENT, ASSIGNMENT AND UNDERTAKING AGREEMENT

THIS AGREEMENT is made the Zday of JUVE 2018 between

(1) Hervé Jean Claude DEBOVES

("THE INVENTOR");

c/o Evotec (UK) Ltd 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UNITED KINGDOM

(2) Evotec (UK) Ltd

("EVOTEC")

114 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RZ

(3) UCB BIOPHARMA SPRL

("UCB BIOPHARMA")

Allée de la Recherche, 60 B-1070 Brussels BELGIUM

WHEREAS

- (A) The Inventor has been determined as being the sole inventor or one of the joint inventors of the invention or inventions entitled SPIROCYCLIC INDOLINES AS IL-17 MODULATORS and identified by the patent family reference PF0110 ("the Invention");
- (B) The Invention is described in a patent application ("the Application"), identified by the following short particulars, which patent application has with the consent of all the parties hereto been filed in the name of **UCB BIOPHARMA** with the patent office shown:

Patent Office	Filing Date	Application Number
UK Patent Office	14 June 2017	1709456.6

- (C) It is the wish and intention of all the parties hereto that:
 - (i) the Application shall continue in the name of UCB BIOPHARMA;
 - (ii) any patent application or like application filed in any country or territory and being directed to the Invention (whether or not claiming priority under the Paris Convention or like arrangement from the Application and including all divisional applications, applications for patents of addition, continuation applications,

continuation-in-part applications, applications for re-issue national applications, patent term extensions, supplementary protection certificates, regional applications and international applications and like corresponding applications) ("Corresponding Application(s)") shall be in the name of and shall vest in UCB BIOPHARMA; and

(iii) any patent granted on the Application or on any Corresponding Application(s) shall be in the name of and shall vest in **UCB BIOPHARMA**.

NOW THIS AGREEMENT WITNESSETH:

- 1. THE INVENTOR ACKNOWLEDGES that:
 - a) he or she made the Invention as part of his or her normal employment duties and the circumstances were such that an invention might reasonably have been expected to result from the carrying out of his or her duties; and
 - b) all his or her right, title, and interest in the invention have transferred to **EVOTEC** by virtue of applicable Law.
- 2. All right, title and interest in the Invention have transferred from EVOTEC to UCB BIOPHARMA by virtue of an agreement dated 4 March 2014 and amendments thereof.

EVOTEC hereby agrees that **UCB BIOPHARMA** has and shall have the exclusive rights to the Invention and all patent applications and resulting patents pertaining to the Invention, as well as the exclusive right to apply for patents, or any other such protection of intellectual property rights for the Invention, including for the avoidance of doubt the Application and the Corresponding Application(s).

- 3. **EVOTEC** and **THE INVENTOR** ACKNOWLEDGE that all right, title and interest in the Invention thereof are vested in **UCB BIOPHARMA** and that **UCB BIOPHARMA** has the exclusive rights to:
 - (i) the Invention;
 - the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto UCB BIOPHARMA absolutely.

- Insofar as the rights in the Invention and the Application are still vested in THE INVENTOR and/or EVOTEC and in consideration of One Dollar (\$1.00) and other good and valuable consideration in hand paid, the receipt and sufficiency whereof are hereby acknowledged, THE INVENTOR and/or EVOTEC HEREBY ASSIGNS to UCB BIOPHARMA:
 - (i) the Invention;
 - (ii) the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) the right to recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto UCB BIOPHARMA absolutely.

- 5. **UCB BIOPHARMA** HEREBY ACCEPTS all that is transferred to it under this Agreement.
- 6. EACH OF THE INVENTOR AND EVOTEC HEREBY UNDERTAKES to do or have done as and when required by UCB BIOPHARMA, or its nominee as UCB BIOPHARMA shall direct, and at the expense of UCB BIOPHARMA, any and all acts and things including the execution of documents necessary or expedient for perfecting the assignments contained herein and/or for giving effect to the wishes and intentions of the parties hereto.
- 7. EACH OF THE INVENTOR AND EVOTEC HEREBY AUTHORISES UCB BIOPHARMA or its nominee and the agents of any of them as UCB BIOPHARMA shall direct to insert here below at (*) the relevant application number and/or any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent Office for recordation of this document:

(4)	110.0	
(*)	US Serial No :	
and/or	PCT Application No:	
	Filing Date :	

- 8. IN THE EVENT THAT ANY OF THE TERMS OF THIS AGREEMENT is held to be invalid, the remainder of the terms shall continue in full force and effect.
- 9. THIS AGREEMENT SHALL BE CONSTRUED in all respects in accordance with law governing Prior Agreement.

IN WITNESS whereof the parties have caused this agreement to be duly executed on the day and year first above written.

This page remains without signatures on purpose – all signatures are executed on follow-up pages (5-7).

Signed by THE INVENTOR

Hervé Jean Claude DEBOVES

Signature:

Place:

EVOTEL UK LTD

Witness signature:

Name:

SIANCARLO TRAM

Address:

114 INNOVATION DRIVE MILTON PARK. ABINGDON,

0X14 4RZ

Place:

EVOTEC UK

Witness signature: 12ICHAI2D JOHN MEARS 02000.

Name:

ESPASITI CHAT GOVAPEZS

Address:

114 Innovation Drive, + (1) bon Park, About day, CX14 422

Place:

Evoluc UK

Signed for and on behalf of Evotec (UK) Ltd

•	KATHRYN NILKES IP HUMAN RESOURCES	KANLAN BASHIR FRIANCE DIRECTOR (UE)
Signature:	rwikej	KBMOLIT ABINIKBONI, UM
Place:	AMSINGDON, UK	Agmisson, Um
Witness signature	Ruon	
Name:	PENNY CHOWN	
Address:	114 Innovation Drive	
Place:	Abingdon, UK	
Witness signature	gue 2	
Name:	SLANLARIS TRAM	
Address:	114 INNOVATION DRIVE	
Place:	ABING DOW, UK	

Signed for and on behalf of UCB BIOPHARMA SPRL
By: Name: Stéphane DROUIN :
Title: Vice President, Head Group Intellectual Property
Signature:
Place: Scaler u/c
Witness signature: <u>Alluj kay</u>
Name: TSAR MY YUMPHA CYS
Address: <u>of 205 Bath (201</u>
Place: <u>SUMON W—</u>
Witness signature:UASedJ20
a series and the second second
Name: <u>KATE SEIGEGE</u>
Address: <u>No 200 Bath Koad</u>
Place: <u>SUOUGHOU</u>

CONFIRMATORY ACKNOWLEDGEMENT, ASSIGNMENT AND UNDERTAKING AGREEMENT

THIS AGREEMENT is made the Lay of Sun 2018 between

(1) Gregory FOULKES

("THE INVENTOR");

c/o Evotec (UK) Ltd 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UNITED KINGDOM

(2) Evotec (UK) Ltd

("EVOTEC")

114 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RZ

(3) UCB BIOPHARMA SPRL

("UCB BIOPHARMA")

Allée de la Recherche, 60 B-1070 Brussels BELGIUM

WHEREAS

- (A) The Inventor has been determined as being the sole inventor or one of the joint inventors of the invention or inventions entitled **SPIROCYCLIC INDOLINES AS IL-17 MODULATORS** and identified by the patent family reference PF0110 ("the Invention");
- (B) The Invention is described in a patent application ("the Application"), identified by the following short particulars, which patent application has with the consent of all the parties hereto been filed in the name of **UCB BIOPHARMA** with the patent office shown:

Patent Office	Filing Date	Application Number
UK Patent Office	14 June 2017	1709456.6

- (C) It is the wish and intention of all the parties hereto that:
 - the Application shall continue in the name of UCB BIOPHARMA;
 - (ii) any patent application or like application filed in any country or territory and being directed to the Invention (whether or not claiming priority under the Paris Convention or like arrangement from the Application and including all divisional applications, applications for patents of addition, continuation applications,

continuation-in-part applications, applications for re-issue national applications, patent term extensions, supplementary protection certificates, regional applications and international applications and like corresponding applications) ("Corresponding Application(s)") shall be in the name of and shall vest in **UCB BIOPHARMA**; and

(iii) any patent granted on the Application or on any Corresponding Application(s) shall be in the name of and shall vest in **UCB BIOPHARMA**.

NOW THIS AGREEMENT WITNESSETH:

- 1. THE INVENTOR ACKNOWLEDGES that:
 - a) he or she made the Invention as part of his or her normal employment duties and the circumstances were such that an invention might reasonably have been expected to result from the carrying out of his or her duties; and
 - b) all his or her right, title, and interest in the invention have transferred to **EVOTEC** by virtue of applicable Law.
- 2. All right, title and interest in the Invention have transferred from **EVOTEC** to **UCB BIOPHARMA** by virtue of an agreement dated 4 March 2014 and amendments thereof.

EVOTEC hereby agrees that **UCB BIOPHARMA** has and shall have the exclusive rights to the Invention and all patent applications and resulting patents pertaining to the Invention, as well as the exclusive right to apply for patents, or any other such protection of intellectual property rights for the Invention, including for the avoidance of doubt the Application and the Corresponding Application(s).

- 3. **EVOTEC** and **THE INVENTOR** ACKNOWLEDGE that all right, title and interest in the Invention thereof are vested in **UCB BIOPHARMA** and that **UCB BIOPHARMA** has the exclusive rights to:
 - (i) the Invention;
 - (ii) the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto UCB BIOPHARMA absolutely.

- Insofar as the rights in the Invention and the Application are still vested in THE INVENTOR and/or EVOTEC and in consideration of One Dollar (\$1.00) and other good and valuable consideration in hand paid, the receipt and sufficiency whereof are hereby acknowledged, THE INVENTOR and/or EVOTEC HEREBY ASSIGNS to UCB BIOPHARMA:
 - (i) the Invention;
 - (ii) the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) the right to recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto **UCB BIOPHARMA** absolutely.

- 5. **UCB BIOPHARMA** HEREBY ACCEPTS all that is transferred to it under this Agreement.
- 6. EACH OF **THE INVENTOR** AND **EVOTEC** HEREBY UNDERTAKES to do or have done as and when required by **UCB BIOPHARMA**, or its nominee as **UCB BIOPHARMA** shall direct, and at the expense of **UCB BIOPHARMA**, any and all acts and things including the execution of documents necessary or expedient for perfecting the assignments contained herein and/or for giving effect to the wishes and intentions of the parties hereto.
- 7. EACH OF THE INVENTOR AND EVOTEC HEREBY AUTHORISES UCB BIOPHARMA or its nominee and the agents of any of them as UCB BIOPHARMA shall direct to insert here below at (*) the relevant application number and/or any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent Office for recordation of this document:

(*)	US Serial No :	
and/or	PCT Application No :	
	Filing Date :	

- 8. IN THE EVENT THAT ANY OF THE TERMS OF THIS AGREEMENT is held to be invalid, the remainder of the terms shall continue in full force and effect.
- 9. THIS AGREEMENT SHALL BE CONSTRUED in all respects in accordance with law governing Prior Agreement.

IN WITNESS whereof the parties have caused this agreement to be duly executed on the day and year first above written.

This page remains without signatures on purpose – all signatures are executed on follow-up pages (5-7).

Signed by THE INVENTOR

Gregory FOULKES

Signature:	_654kz	
Place:	Evotec UK	
Witness signature:	gues Ce	
Name:	VGIANCARO TRAN	
Address:	112-14 INNOVATION DRIVE, MILTON	PARK, OXK, GRA
Place:	EVOTER UK	
Witness signature:		
Name:	Dishard John Mag/5	
Address:	12 Immoration Drive, Millon	Pelc, Abrydon, Crit
Place:	EVOLEC.	

Signed for and on behalf of Evotec (UK) Ltd

· •	CATHRYN WILKES P HUMAN RESCURCES	Kameani Finance	Preson (ne)
Signature:	Kurikly	KIRAN Alingoon	e & & Jamin
Place:	ABINGDON, LIK	WRINGBOU	, Om
Witness signature	fluor		
Name:	PENNY CHOUN		
Address;	114 Innovation Drive	•	
Place:	Abinplon, We.		
Witness signature:	gue 2		
Name:	GIANCARG TRAM		
Address:	Illy INNOVATION DRIVE		
Place:	ARINGDON, UK		

Signed for and on I	pehalf of UCB BIOPHARMA SPRL		
By: Name: Stép	phane DROUIN :		
Title: Vice	President, Head Group Trite lectual Property		
Signature:			
Place:	SLOUGH, UK		
Witness signature:			
Name:	SARAH HUMPURCUS		
Address:	do 205 Bath Road		
Place:	SLOUEH, UK		
Witness signature:	_b#eg/200/		
Name:	KATE SEIZBEER		
Address:	elo 205 Bath Road		
Place:	SLUGH, UL		

CONFIRMATORY ACKNOWLEDGEMENT, ASSIGNMENT AND UNDERTAKING AGREEMENT

THIS AGREEMENT is made the Valay of July 2018 between

(1) Robert James TOWNSEND

("THE INVENTOR");

c/o Evotec (UK) Ltd 114 Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, UNITED KINGDOM

(2) Evotec (UK) Ltd

("EVOTEC")

114 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RZ

(3) UCB BIOPHARMA SPRL

Allée de la Recherche, 60 B-1070 Brussels BELGIUM ("UCB BIOPHARMA")

WHEREAS

- (A) The Inventor has been determined as being the sole inventor or one of the joint inventors of the invention or inventions entitled SPIROCYCLIC INDOLINES AS IL-17 MODULATORS and identified by the patent family reference PF0110 ("the Invention");
- (B) The Invention is described in a patent application ("the Application"), identified by the following short particulars, which patent application has with the consent of all the parties hereto been filed in the name of **UCB BIOPHARMA** with the patent office shown:

Patent Office	Filing Date	Application Number
UK Patent Office	14 June 2017	1709456.6

- (C) It is the wish and intention of all the parties hereto that:
 - (i) the Application shall continue in the name of UCB BIOPHARMA;
 - (ii) any patent application or like application filed in any country or territory and being directed to the Invention (whether or not claiming priority under the Paris Convention or like arrangement from the Application and including all divisional applications, applications for patents of addition, continuation applications,

continuation-in-part applications, applications for re-issue national applications, patent term extensions, supplementary protection certificates, regional applications and international applications and like corresponding applications) ("Corresponding Application(s)") shall be in the name of and shall vest in **UCB BIOPHARMA**; and

(iii) any patent granted on the Application or on any Corresponding Application(s) shall be in the name of and shall vest in **UCB BIOPHARMA**.

NOW THIS AGREEMENT WITNESSETH:

- 1. **THE INVENTOR** ACKNOWLEDGES that:
 - a) he or she made the Invention as part of his or her normal employment duties and the circumstances were such that an invention might reasonably have been expected to result from the carrying out of his or her duties; and
 - b) all his or her right, title, and interest in the invention have transferred to **EVOTEC** by virtue of applicable Law.
- 2. All right, title and interest in the Invention have transferred from EVOTEC to UCB BIOPHARMA by virtue of an agreement dated 4 March 2014 and amendments thereof.

EVOTEC hereby agrees that **UCB BIOPHARMA** has and shall have the exclusive rights to the Invention and all patent applications and resulting patents pertaining to the Invention, as well as the exclusive right to apply for patents, or any other such protection of intellectual property rights for the Invention, including for the avoidance of doubt the Application and the Corresponding Application(s).

- 3. **EVOTEC** and **THE INVENTOR** ACKNOWLEDGE that all right, title and interest in the Invention thereof are vested in **UCB BIOPHARMA** and that **UCB BIOPHARMA** has the exclusive rights to:
 - (i) the Invention;
 - the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto UCB BIOPHARMA absolutely.

- 4. Insofar as the rights in the Invention and the Application are still vested in THE INVENTOR and/or EVOTEC and in consideration of One Dollar (\$1.00) and other good and valuable consideration in hand paid, the receipt and sufficiency whereof are hereby acknowledged, THE INVENTOR and/or EVOTEC HEREBY ASSIGNS to UCB BIOPHARMA:
 - (i) the Invention;
 - (ii) the Application, the benefit of the Application, all right, title and interest therein (including the right to make Corresponding Application(s) and obtain patents or like forms of protection for the Invention in any country or territory of the world together with the right to claim priority of the Application under the Paris Convention or any other patent treaty, law or convention) and all the rights, powers, liberties and immunities belonging thereto or accrued therefrom free from all encumbrances to the intent that any patent granted pursuant to the Application or to any Corresponding Application(s) shall be in the name of and vested in UCB BIOPHARMA;
 - (iii) the right to recover and take all such proceedings as may be necessary for the recovery of damages, an account of profits or other relief in respect of all infringements of any patent or patents granted pursuant to the Application or to any Corresponding Application(s) whether such infringements take place before or after the date of this Agreement;

TO HOLD unto **UCB BIOPHARMA** absolutely.

- UCB BIOPHARMA HEREBY ACCEPTS all that is transferred to it under this Agreement.
- 6. EACH OF THE INVENTOR AND EVOTEC HEREBY UNDERTAKES to do or have done as and when required by UCB BIOPHARMA, or its nominee as UCB BIOPHARMA shall direct, and at the expense of UCB BIOPHARMA, any and all acts and things including the execution of documents necessary or expedient for perfecting the assignments contained herein and/or for giving effect to the wishes and intentions of the parties hereto.
- 7. EACH OF **THE INVENTOR** AND **EVOTEC** HEREBY AUTHORISES **UCB BIOPHARMA** or its nominee and the agents of any of them as **UCB BIOPHARMA** shall direct to insert here below at (*) the relevant application number and/or any further identification which may be necessary or desirable in order to comply with the rules of the United States Patent Office for recordation of this document:

(*)	US Serial No :	
and/or	PCT Application No:	
	Filing Date :	

- 8. IN THE EVENT THAT ANY OF THE TERMS OF THIS AGREEMENT is held to be invalid, the remainder of the terms shall continue in full force and effect.
- 9. THIS AGREEMENT SHALL BE CONSTRUED in all respects in accordance with law governing Prior Agreement.

IN WITNESS whereof the parties have caused this agreement to be duly executed on the day and year first above written.

This page remains without signatures on purpose – all signatures are executed on follow-up pages (5-7).

Signed by THE INVENTOR

Robert James TOWNSEND

Signature:	25 Can 1)	
Place:	EVOTEC UKLEDY	
Witness signature	SIANCARIO TRANI	
Name:	SIANCARLO TRANI	
Address:	114 INNOVATION DRIVE, MILTON PARK .	BINGADN
Place:	EVOTEC UK	XI4 GRE
Witness signature	e: <u>030-20</u>	
Name:	QICHARD JOHN MEARS	
Address:	114 IMMOVATION DRIVE, MILTON PARK	LACED PLAZONA,
Place:	evates uk	OX 1st +15 mm

Signed for and on behalf of UCB BIOPHARMA SPRI.

By: Name: Stéphane DROUIN:

Title: Vice President, Head Group Intellectual Property

Signature:

Place: SLOUGH, UK

Witness signature: SARAH HUMPHONE

Address: Clo Jos Bath Road

Witness signature: SLOUGH, MA

Witness signature: SLOUGH, MA

Witness signature: SLOUGH, MA

Place: SLOUGH,

7